PALM BEACH GARDENS, Fla., Oct. 19, 2026 (GLOBE NEWSWIRE) — A new warning letter issued by the U.S. Food and Drug Administration to Olympus Corporation is raising renewed concerns about the medical device manufacturer’s quality management systems, particularly in light of its history of patient infections, failures to report serious adverse events, and previous regulatory violations.
Olympus disclosed on October 13 that it had received an FDA warning letter dated October 7, 2026, following inspections conducted in late 2025. Unlike enforcement actions focused on a particular device or manufacturing location, the latest warning addresses quality management systems and related processes at six Olympus facilities across Japan, Germany, and the United States.
For Katherine A. Kiziah, a partner at Rafferty Domnick Cunningham & Yaffa (RDCY) whose practice focuses on complex product liability, mass tort, pharmaceutical, and medical device litigation, the development raises important questions about whether Olympus has adequately addressed problems that have attracted regulatory attention for years.
“This is not a company encountering FDA scrutiny for the first time,” said Kiziah. “Olympus has a documented history of serious problems involving medical device safety, regulatory reporting, and quality control. What concerns me about this latest warning is that we’re no longer talking about an isolated issue at one facility. The FDA’s concerns now extend across multiple facilities in several countries. That raises an obvious question: How much more needs to happen before these problems are fully resolved?”
The October 7 warning letter follows FDA inspections at Olympus Medical Systems facilities in Hachioji and Hinode, Japan; Aomori Olympus and Shirakawa Olympus in Japan; Olympus Winter & IBE GmbH in Hamburg, Germany; and Gyrus ACMI, Inc. in Brooklyn Park, Minnesota.
According to Olympus, the FDA’s warning addresses the adequacy of the company’s responses to quality management system and process observations previously documented during those inspections. Olympus says it has already implemented significant corrective and preventive actions and intends to submit a comprehensive response to the FDA within 15 business days of receiving the letter.
A History of Serious Regulatory Problems
The latest warning comes against a backdrop of significant regulatory and criminal enforcement actions involving Olympus medical devices.
In December 2018, Olympus Medical Systems Corporation pleaded guilty to failing to submit FDA-required adverse event reports involving infections associated with its duodenoscopes. The company agreed to pay $85 million in fines and forfeiture and implement additional compliance measures. The unreported or inadequately reported events included infections affecting patients at European hospitals.
In January 2023, the FDA announced additional warning letters involving Olympus and a subsidiary, citing violations of medical device reporting requirements and quality system regulations. The agency identified deficiencies involving complaint handling, manufacturing processes, and the timely reporting of events involving potentially dangerous medical devices.
The concerns continued.
In June 2025, the FDA announced import alerts affecting certain Olympus medical devices manufactured in Japan, citing outstanding quality system violations despite extensive efforts to address the company’s compliance problems. The affected categories included bronchoscopes, ureterorenoscopes, laparoscopes, and automated endoscope reprocessors.
For Kiziah, the progression of these events is difficult to ignore.
“When a manufacturer has already faced criminal penalties, repeated FDA warnings, and restrictions involving certain products, the public has every reason to expect meaningful and lasting corrective action,” she said. “Yet here we are, years later, confronting another warning about quality management processes. Patients should not have to wonder whether a medical device manufacturer’s promises to improve are actually being carried out throughout the organization.”
Why Company-Wide Quality Systems Matter
Medical device safety depends on far more than the design of an individual product. Manufacturers must maintain effective systems for identifying potential defects, investigating complaints, documenting adverse events, evaluating risks, and implementing corrective measures.
Failures in those systems can have consequences that extend well beyond a single device or product line.
For reusable medical devices, including certain endoscopes, effective manufacturing controls and timely identification of safety problems are particularly important. These devices are used in procedures involving vulnerable patients, and failures involving contamination, damaged components, or inadequate reporting can potentially expose patients to serious harm.
“One of the lessons from years of medical device litigation is that patient safety problems don’t always begin with a single defective product,” Kiziah said. “Sometimes they begin with a complaint that wasn’t properly investigated, a warning sign that wasn’t acted upon, or a corrective action that never adequately addressed the underlying problem. Those are the kinds of systems that must work consistently, regardless of where a device is manufactured.”
Olympus has stated that the new warning letter does not require a product recall, restrict its ability to manufacture or distribute products, or prevent it from seeking FDA clearance for new devices. The company has also said that customers do not need to take additional action as a result of the warning letter and that its products remain safe and effective when used according to their instructions.
The warning letter does not, by itself, establish that any particular Olympus device is defective or that a patient has been injured.
Nevertheless, RDCY believes the latest development deserves careful public scrutiny, particularly given the company’s previous regulatory history.
“There’s a difference between telling regulators that corrective action has been taken and demonstrating that the problems have actually been fixed,” Kiziah said. “The public deserves confidence that Olympus is doing more than responding to individual inspections. It deserves confidence that the company has systems capable of identifying problems, addressing them promptly, and preventing them from happening again.”
Continued Scrutiny and Patient Accountability
Rafferty Domnick Cunningham & Yaffa represents individuals and families in complex litigation involving dangerous products, medical devices, and other forms of alleged corporate misconduct. The firm closely monitors FDA enforcement developments and their potential implications for patient safety.
Kiziah emphasized that the most important question is not simply how Olympus responds to the latest warning, but whether its response produces lasting changes.
“Regulatory compliance is not a public relations exercise. It’s a patient safety obligation,” she said. “When people undergo medical procedures, they have to trust that the equipment being used has been manufactured and monitored appropriately. That trust should be earned through demonstrated compliance, accountability, and a willingness to confront problems before patients are harmed.”
About Rafferty Domnick Cunningham & Yaffa
Rafferty Domnick Cunningham & Yaffa is a leading Florida law firm dedicated to advocating for victims of mass torts, medical malpractice and corporate negligence. With a track record of holding powerful institutions accountable, the firm fights for justice on behalf of individuals and families affected by preventable harm.
Press Contact:
Natasha Diemer
Chief Strategy Officer (CSO)
Rafferty Domnick Cunningham & Yaffa
Phone: (561) 516-5168
Email: Natasha@pbglaw.com
Agency Contact:
Bridget Mercuri
Public Relations and Earned Media Director
AMPLIFY
Phone: (908)-612-3515
Email: bridget@amplifylaw.ai.
Media gallery
